GLP1R and type 2 diabetes mellitus: Seven different GLP-1 receptor agonists have been approved by the US Food and Drug Administration for the treatment of type 2 diabetes (i.e., exenatide, liraglutide, dulaglutide, albiglutide, lixisenatide, semaglutide, and tirzepatide).